NMN vs NR: Which NAD+ Precursor Has Better Evidence?

Disclaimer: This article is for educational purposes only and does not constitute medical advice. NMN and NR are dietary supplements, not medicines. Consult a qualified healthcare professional before starting any supplementation programme, particularly if you have a medical condition or take prescription medications.

The NAD+ Supplement Question

Walk into any supplement store or scroll through a wellness newsletter and you will encounter two names repeatedly: NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both are marketed as ways to raise NAD+ levels — the coenzyme that powers cellular energy metabolism — and both carry claims linking them to longevity, metabolic health, and sustained energy.

The marketing pitch is grounded in real biology. NAD+ (nicotinamide adenine dinucleotide) does decline with age, and this decline has been associated with reduced mitochondrial efficiency, impaired DNA repair, and diminished cellular resilience. The question is not whether NAD+ matters — it clearly does — but whether these supplements raise NAD+ in ways that translate into meaningful human health outcomes. The human clinical trial evidence is smaller, more recent, and more nuanced than the supplement industry typically acknowledges.

This article unpacks the biology, walks through the available clinical evidence for each compound, and offers a frank assessment of what the research does and does not support.

---

NAD+ Biology: What You Actually Need to Know

NAD+ is not one molecule with one job. It operates across multiple critical biological roles simultaneously.

Electron carrier in energy metabolism. In its oxidised (NAD+) and reduced (NADH) forms, NAD+ shuttles electrons through glycolysis, the tricarboxylic acid (TCA) cycle, and oxidative phosphorylation. This electron transfer is how cells extract ATP from glucose and fatty acids. Without adequate NAD+, mitochondrial efficiency drops.

Substrate for sirtuins. The sirtuin family (SIRT1 through SIRT7) are NAD+-dependent deacylases with broad roles in metabolic regulation, gene expression, stress response, and lifespan extension across model organisms. Sirtuins consume NAD+ during their catalytic cycle, which means NAD+ availability directly limits sirtuin activity. This sirtuin–NAD+ connection is the core of the longevity hypothesis underlying these supplements.

Substrate for PARPs. Poly(ADP-ribose) polymerases use NAD+ to tag damaged DNA and recruit repair machinery. During periods of oxidative stress or genotoxic injury, PARP activity surges and can rapidly deplete local NAD+ pools, temporarily competing with sirtuins for the same substrate.

CD38: the NAD+ consumer that increases with age. CD38 is an ectoenzyme expressed on immune cells, cardiac muscle, and other tissues that hydrolyses NAD+ at very high rates. CD38 expression increases with age and inflammation, and it is now understood to be a major driver of the age-related decline in NAD+ — not reduced synthesis alone. This point matters because it suggests that raising precursor supply addresses only one side of the equation.

Synthesis pathways. Cells can generate NAD+ via the de novo pathway (starting from tryptophan, through kynurenine and quinolinic acid intermediates), through the Preiss–Handler pathway (from niacin/nicotinic acid), or via the salvage pathway (recycling nicotinamide back to NMN and then to NAD+). The salvage pathway is quantitatively dominant in most tissues, which is why NAD+ precursor supplements focus on feeding into it.

---

The Precursor Hierarchy

Understanding where NMN and NR sit in the metabolic pathway clarifies why they have become the dominant supplement candidates over simpler and cheaper options like plain niacin or nicotinamide.

The pathway runs broadly: tryptophan → nicotinic acid (niacin) → nicotinamide (Nam) → NMN → NR → NAD+. In practice, NR is phosphorylated to NMN by NR kinases (NRK1/2), and NMN is then adenylated to NAD+ by NMNAT enzymes. Niacin causes flushing via prostaglandin D2 release, which limits its tolerability at effective doses. Plain nicotinamide at high doses can inhibit sirtuins directly — a theoretical safety concern that keeps it out of favour for longevity applications.

NMN sits one step closer to NAD+ than NR does. However, the route by which orally ingested NMN reaches intracellular NAD+ has been debated. Work by multiple researchers suggests that much orally administered NMN is dephosphorylated to NR in the gut lumen or at the intestinal surface before absorption, then re-phosphorylated intracellularly back to NMN. A specific transporter, Slc12a8, was identified in mouse intestine and shown to transport NMN directly — but whether this transporter is functionally significant in humans at supplemental doses remains under investigation. The clinical significance of the NMN-to-NR conversion is likely small: both appear to raise blood and tissue NAD+ metabolites when given orally.

---

NR: Clinical Evidence Review

NR has been studied in human trials since approximately 2016, giving it a longer clinical track record than NMN.

Dellinger et al. (2017) — the Elysium BASIS trial. This randomised, double-blind, placebo-controlled trial enrolled 120 healthy adults aged 60 to 80 years. Participants received either NR 250 mg plus pterostilbene 50 mg (BASIS), double the dose, or placebo for eight weeks. Both active doses raised whole blood NAD+ significantly: the standard dose increased NAD+ by approximately 40% and the double dose by approximately 90%. The trial was primarily a biomarker study; no cognitive, metabolic, or functional endpoints were pre-specified as primary outcomes. This limits what can be concluded about clinical benefit.

ChromaDex clinical programme. ChromaDex (the manufacturer of Tru Niagen/NIAGEN) has sponsored multiple studies confirming that NR consistently raises blood NAD+ metabolites across healthy adults and various clinical populations. The dose–response relationship is reasonably well characterised: 300–1000 mg per day produces NAD+ elevations of 40–100% in whole blood.

Airhart et al. (2017) — heart failure patients. In a small pilot RCT in patients with heart failure and preserved ejection fraction, NR 500 mg twice daily for 12 weeks raised NAD+ metabolites in blood but did not improve peak oxygen consumption (VO2 peak), six-minute walk distance, or quality of life versus placebo. This is an important signal that raising blood NAD+ does not automatically translate into functional improvement, at least in this disease context.

The core limitation of NR trials. The majority of NR human studies are short (six to twelve weeks), use blood NAD+ as the primary endpoint, and are adequately powered only to detect biochemical changes — not clinical outcomes. Blood NAD+ elevation is a mechanistic biomarker, not a health outcome. Whether NR supplementation reduces disease risk, improves long-term physical function, or extends healthspan in humans remains undemonstrated.

---

NMN: Clinical Evidence Review

NMN human trials are fewer in number but several have included objective functional endpoints, which makes them particularly informative.

Igarashi et al. (2022) — Keio University / Michigan collaboration. This was a 12-week randomised, double-blind, placebo-controlled trial in 36 middle-aged healthy adults (aged 45 to 60) randomised to NMN 250 mg per day or placebo. The primary finding was a significant increase in NAD+ levels in skeletal muscle (measured by biopsy and metabolomics), alongside a statistically significant improvement in six-minute walk test distance in the NMN group versus placebo. Walk speed improvement in a middle-aged healthy population is a meaningful functional endpoint, and this study is one of the strongest pieces of human evidence for NMN to date.

Yi et al. (2023) — Chinese RCT in older adults. This trial randomised older adults to NMN 300 mg per day versus placebo and reported improvements in self-reported fatigue and physical performance measures in the NMN group. Effect sizes were modest but consistent with a biologically plausible benefit in an older population where NAD+ decline is more pronounced.

Yoshino et al. (2021) — Washington University, published in Science. This rigorous, placebo-controlled trial gave NMN 250 mg per day to obese postmenopausal women with prediabetes for 10 weeks. The NMN group showed improved insulin sensitivity in skeletal muscle — assessed via hyperinsulinaemic–euglycaemic clamp, the gold standard method. Crucially, the researchers also found molecular evidence of enhanced NAD+ utilisation in muscle tissue, including upregulation of genes involved in muscle remodelling. This is among the highest-quality NMN human trials published and adds a clinically relevant metabolic endpoint to the evidence base.

---

Honest Head-to-Head Assessment

No adequately powered direct comparison RCT between NMN and NR in humans currently exists. Drawing firm conclusions about superiority is therefore premature.

What the evidence shows:

• Both compounds reliably raise blood and tissue NAD+ metabolites in humans at doses of 250–500 mg per day.
• NMN has a small but emerging body of evidence linking supplementation to objective functional outcomes (walk distance, insulin sensitivity) in controlled human trials.
• NR has broader biomarker evidence across a wider range of populations, but fewer trials with functional endpoints.
• Neither compound has multi-year safety data or long-term clinical outcome trials (cardiovascular events, cancer incidence, mortality) in humans.
• The animal longevity data — which is substantial and compelling for both compounds — does not directly translate to humans, where dose scaling, metabolic context, and lifespan are fundamentally different.

If forced to rank on current human evidence quality and functional endpoint data, NMN has a modest edge. But the honest answer for any individual is that neither supplement has been proven to extend human healthspan.

---

Food Sources: Real but Minimal

NR is found in small amounts in cow's milk, yeast, and edamame. NMN has been detected in broccoli, edamame, avocado, cucumber, and tomato. The concentrations, however, are in the microgram-per-gram range. Supplemental doses used in trials are in the range of 250–500 mg — meaning you would need to eat implausibly large quantities of these foods to approach supplemental doses from diet alone. Food sources are not a meaningful route to the NAD+ elevation seen in clinical trials. That said, a diet rich in these foods delivers broader nutritional benefits beyond any single NAD+ precursor.

For a broader look at how dietary choices support cellular resilience, the resistant starch foods guide covers another well-evidenced nutritional strategy for metabolic health.

---

Absorption, Formulations, and Stability

The supplement market offers NMN and NR in several delivery formats, including standard capsules, sublingual tablets, and liposomal preparations. Proponents of sublingual NMN argue that bypassing first-pass gut conversion to NR allows more NMN to enter circulation intact. Some pharmacokinetic data supports modestly higher plasma NMN in sublingual versus oral delivery, but whether this translates to meaningfully higher tissue NAD+ or better clinical outcomes is not established.

Standard oral NMN and NR are both reasonably stable in capsule form when stored correctly (cool, dark, low humidity). Opened bottles in humid environments may degrade faster. Both are water-soluble and are best absorbed on an empty stomach or with a light meal, though food effects are minor.

---

Safety Profile and Side Effects

Both NMN and NR appear well-tolerated in clinical trials up to 12 months at doses of up to 1000 mg per day for NR and 1200 mg per day for NMN. Reported adverse effects are generally mild and infrequent: nausea, headache, and fatigue at higher doses in a minority of participants. Neither compound produces the cutaneous flushing associated with pharmacological doses of nicotinic acid (niacin), because they do not activate the GPR109A receptor responsible for that response.

A theoretical concern worth noting: both NMN and NR are metabolised partly to free nicotinamide (Nam) in vivo. At very high supplemental doses, elevated circulating Nam could potentially inhibit SIRT1 activity — the opposite of the intended effect. This has not been demonstrated as a clinical problem in existing trials, but it is a reason to treat very high-dose protocols (above 1000 mg/day) with caution in the absence of further safety data.

B vitamin status is relevant context. Riboflavin (B2) is a cofactor required for NRK enzyme activity, and pyridoxine (B6) plays roles in tryptophan-to-NAD+ conversion. Deficiency in either could theoretically limit NAD+ synthesis from precursors. A well-rounded B vitamin intake — addressed in the vitamin B12 forms compared article — supports the broader metabolic context in which NAD+ precursors work.

---

Practical Considerations for Nutrition-Focused Use

Supplementation is not permanent uplift. Blood and tissue NAD+ levels return toward baseline within days of stopping supplementation. This is a continuous maintenance model, not a one-time correction.

Exercise is a potent NAD+ strategy. Both aerobic exercise and resistance training activate AMPK and SIRT1 signalling, raising NAD+ levels and NAD+-dependent metabolic pathways independently of supplementation. Endurance training in particular increases mitochondrial NAD+ pool capacity. No supplement should be positioned as a substitute for regular physical activity.

Dietary co-factors matter. Beyond riboflavin and B6, adequate tryptophan intake (from protein-rich whole foods) supports de novo NAD+ synthesis. Caloric restriction and time-restricted eating also support sirtuin activity via reduced NADH/NAD+ ratios. The gut-brain axis nutrition strategies article explores how systemic dietary patterns interact with these metabolic pathways.

Who might have the strongest case for supplementation? Older adults (where NAD+ decline is steepest), those with metabolic conditions such as prediabetes or obesity, and individuals recovering from significant physiological stress may have the most to gain from raising NAD+ via precursor supplementation. In younger, healthy, physically active individuals with good dietary habits, the marginal benefit is likely smaller.

Dose range in trials. Most positive human trials used 250–500 mg per day of either NMN or NR. There is no strong human evidence that higher doses provide proportionally greater clinical benefit, and the safety profile above 1000 mg per day is less well characterised.

---

Conclusion

NMN and NR are among the most scientifically credible supplements in the longevity and metabolic health space — not because the evidence is definitive, but because the underlying biology is sound and the human trial data, while limited, is genuinely promising. Both compounds raise NAD+ in humans. NMN has the more interesting recent trial data on functional endpoints; NR has the longer human biomarker track record. Neither has been proven to extend human lifespan or prevent age-related disease in long-term clinical trials.

For those interested in NAD+ and longevity research, the science is evolving rapidly. The most honest position is that NMN and NR represent a biologically plausible nutritional strategy for supporting cellular energy metabolism in the context of age-related NAD+ decline — best used alongside, not instead of, the well-established foundations: regular exercise, adequate sleep, whole-food dietary patterns, and consistent B vitamin sufficiency.